Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PET, ANW, MRR

Global Animal Feed Phytogenics Research Report 2023-2030: Advanced Microencapsulation and Delivery Technologies Fuels Growth Opportunities


DUBLIN, Aug. 4, 2023 /PRNewswire/ -- The "Global Animal Feed Phytogenics Growth Opportunities" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo


The study period is 2020-2030, with 2022 as the base year and 2023-2030 as the forecast period. The report's scope only includes the animal feed application of phytogenics and excludes veterinary drugs and drenching applications.

Increasing antimicrobial resistance in pathogenic bacteria has resulted in many countries banning AGPs for animal nutrition. Growing concerns worldwide over AGPs in animal nutrition have resulted in efforts to use alternative ingredients that can effectively replace AGPs; phytogenics is one such alternative.

The analysis shows that Europe dominated the global animal feed phytogenics market in 2022 due to stringent regulations on the use of AGPs since 2006 in EU countries and a high preference for natural ingredients. The publisher expects APAC to show the fastest growth during the forecast period due to growth in compound feed production, the adoption of intensive animal farming practices, and regulatory restrictions on using AGPs by different countries in the region.

The analyst also considered the impact of the COVID-19 pandemic and other geopolitical situations, such as the Russia-Ukraine war, in the analysis. Additional vital information includes notable competitors for each product type; market drivers, restraints, and trends; acquisitions; and product launches. Most importantly, we explore growth opportunities stakeholders can monetize over the next few years.

Growth Opportunity Analysis

Key Topics Covered:

Strategic Imperatives

Growth Opportunity Analysis

Regional Analysis

For more information about this report visit https://www.researchandmarkets.com/r/e03ydp

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 10:10
Kite, a Gilead Company , today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain. Four...

at 10:10
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced that the Japanese Patent Office has issued Japanese Patent No. 7474463 for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic...

at 10:10
Genmab A/S announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain...

at 10:07
CorePlus www.corepluspr.com, a precision pathology organization, announced today that it is the first laboratory in the world to operationalize the Techcyte AI algorithm and quality control workflow for cytology-based cervical cancer screening. After...

at 10:07
A new survey from the American Academy of Dermatology revealed that Generation Z adults, ages 18-25, are at risk for skin cancer due to increasing rates of tanning and burning. To encourage safe sun habits, the AAD is shining a spotlight on the ways...

at 10:05
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European...



News published on and distributed by: